Dr. Heba Abdelmegeed, National Research Centre, Egypt
Dr. Heba Abdelmegeed is a senior researcher at the Chemistry of Natural Compounds Department, National Research Centre, Cairo, Egypt. 🎓 She earned her Ph.D. in Immunology (Magna Cum Laude) from Technische Universität Dresden, Germany, and a Master’s in Pharmaceutical Sciences from Hokkaido University, Japan. With expertise in immunology, molecular biology, and cancer biology, she has authored impactful research on cancer therapeutics and immunomodulation. 🧪 Her diverse academic journey spans Germany, Japan, and Egypt, with multiple publications, awards, and international conference contributions. Driven by scientific curiosity, she continues to explore cutting-edge innovations in cancer biology and immunological research.
Publication Profile
Google Scholar
Education
Dr. Heba Abdelmegeed is a distinguished immunologist with a rich academic journey across three continents. She earned her Ph.D. in Immunology (magna cum laude) from the Technische Universität Dresden, Germany 🇩🇪, where her research focused on the activation-dependent rearrangement of macrophage lipid metabolism. Prior to that, she completed her M.Sc. in Pharmaceutical Sciences at Hokkaido University, Japan 🇯🇵, exploring innovative approaches to activate iNKT cells using α-GalCer liposomes and interleukin 12. Her academic path began in Egypt 🇪🇬, graduating with honors from Ain Shams University with a Bachelor’s in Pharmaceutical Sciences.
Experience
Dr. Heba Abdelmegeed is a dedicated researcher with a diverse and global professional background in pharmaceutical sciences. Since August 2020, she has served as a Senior Researcher at the Chemistry of Natural Compounds Department, NRC, Egypt 🇪🇬. Previously, she was a Ph.D. candidate at the Technical University of Dresden, Germany 🇩🇪, from 2015 to 2020. She also held the role of Assistant Researcher at NRC and was a Master’s candidate at Hokkaido University, Japan 🇯🇵. Her career began as a Quality Control Analyst at NODCAR, reflecting her strong foundation in drug analysis and research.
Research Focus
Dr. Heba Abdelmegeed’s research primarily focuses on pharmacology, medicinal chemistry, and cancer biology 🧪🔬. Her work includes developing novel anti-cancer compounds, such as quinoline and pyridine derivatives, targeting tubulin polymerization and cyclin-dependent kinases to inhibit tumor growth 🎯💊. She also explores nanoparticle drug delivery systems for enhanced antimicrobial and wound healing effects 🧫🩹. Additionally, Dr. Abdelmegeed investigates inflammation, mitochondrial function, and lipid metabolism in cancer and endocrine disorders 🔥🦠⚙️. Her multidisciplinary approach bridges molecular biology, synthetic chemistry, and computational studies to advance therapeutic strategies against cancer and infectious diseases.
Publication Top Notes
In Vivo Inverse Correlation in the Activation of Natural Killer T Cells Through Dual-Signal Stimulation via a Combination of α-Galactosylceramide–Loaded Liposomes and …
Succinate mediates inflammation-induced adrenocortical dysfunction
Coumarins: quorum sensing and biofilm formation inhibition
New heterocycles from dehydroacetic acid (DHA). Synthesis, antimicrobial activity, DNA gyrase inhibition, antioxidant activity, and molecular docking study
Chitosan nanoparticles of new chromone-based sulfonamide derivatives as effective anti-microbial matrix for wound healing acceleration
Synthetic Analogs of Marine Alkaloid Aplysinopsin Suppress Anti-Apoptotic Protein BCL2 in Prostate Cancer
Obesity-associated lipidomic remodeling of the adrenal gland indicates an important role of the FADS2-arachidonic acid axis in adrenocortical hormone production
INFLAMMATION–INDUCED DOWNREGULATION OF SUCCINATE DEHYDROGENASE REGULATES ADRENOCORTICAL FUNCTION
Exploring the antitumor potential of novel quinoline derivatives via tubulin polymerization inhibition in breast cancer; design, synthesis and molecular docking
Mitochondria in cancer: a comprehensive review, bibliometric analysis, and future perspectives
Anti colorectal cancer activity and in silico studies of novel pyridine nortopsentin analog as cyclin dependent kinase 6 inhibitor